Anti-(human Platelet-derived Growth Factor Receptor~) (human Monoclonal Regn2176 Heavy Chain) Uses, Dosage, Side Effects and more
Anti-(human Platelet-derived Growth Factor Receptor~) (human Monoclonal Regn2176 Heavy Chain) is under investigation in clinical trial NCT02418754 (Study of Intravitreal REGN2176-3 in Participants With Neovascular ("Wet") Age-related Macular Degeneration (AMD)).
| Trade Name | Anti-(human Platelet-derived Growth Factor Receptor~) (human Monoclonal Regn2176 Heavy Chain) |
| Generic | Rinucumab |
| Rinucumab Other Names | Immunoglobulin g4, anti-(human platelet-derived growth factor receptor~) (human monoclonal regn2176 heavy chain), disulfide with human monoclonal regn2176 k-chain, dimer, Rinucumab |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
